Averion Expands Operations to Europe and Names John Shillingford, PhD as President of New Wholly-Owned Subsidiary Averion GmbH
May 23, 2006, Framingham, Massachusetts, USA- Averion Inc. announced today its expansion into Europe through the creation of Averion GmbH, a new wholly-owned subsidiary based in Germany. The Company also announced the appointment of John Shillingford, PhD as President of Averion GmbH.
Averion GmbH will work to develop relationships with European clients as well as run European studies for existing North American clients. The new subsidiary will offer Averion?s full range of services including: Auditing, Biometrics, Clinical Monitoring, Clinical Project Management, Compliance and Validation, Database Development, Data Management, Data Monitoring and Clinical Endpoint Committees, Medical Monitoring, Medical Writing, Metrics Consulting, Pharmacovigilance, Program Planning/Study Design and Regulatory Consulting.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.